Shots:
- Accent to receive ~$446M including up front, pre-clinical, clinical, regulatory, and sales-based milestone along with royalties
- Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor program
- The collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities to develop and commercialize transformative oncology medicines for the treatment of AML
Click here to read the full press release/ article | Ref: Businesswire | Image: Pharma Boardroom
The post Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program first appeared on PharmaShots.
